| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Pediatric living donor liver transplant (LDLT) patients sometimes develops graft fibrosis. Therefore, we have performed serial protocol biopsies. They showed graft fibrosis even if their liver function tests were within normal range. Recently donor specific antibody (DSA) may have a role in graft damage after liver transplantation. We investigated rate of graft fibrosis in pediatric patients after LDLT and the mechanism of fibrosis focusing the DSA.
Twenty three patients who were received the liver during childhood due to biliary atresia enrolled in this study. Graft fibrosis was observed in 17 patients (74%). Positive DSA patients tend to develop graft fibrosis. Further follow up is required to determine the relationship between fibrosis progression and DSA; however, our findings are expected to lead long term alive of pediatric patients after LDLT preventing graft fibrosis.
|
